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Background
Until now, we have all been desperately trying to run 
behind the HIV/AIDS epidemic and catch up with it, but 
despite all our eﬀ orts, the epidemic remains well ahead of 
us. Th e annual estimates of people living with HIV/AIDS, 
new HIV infections and AIDS-related deaths since the 
dawn of the epidemic three decades ago provide undeni-
able justiﬁ cation to this statement. Although we are 
beginning to see some encouraging trends [1] we remain 
far from any epidemiological ideal of control.
In 2009, there were 5.25 million people receiving anti-
retroviral treatment (ART) in low- and middle-income 
countries, which is a 40% coverage of those esti mated to 
be in need of treatment [2]. However, with 2.6 million 
new HIV infections in 2009, for every person started on 
ART, there were two new infections, a sobering statistic 
that belies any claims that we are on top of this epidemic. 
AIDS continues to take its toll, with an estimated 1.8 
million AIDS-related deaths in 2009 [1].
In summary, the backlog is high and the pipeline of 
new HIV/AIDS cases remains wide open. Given the 
enormity of the problem, it is not surprising that all the 
set implementation targets, such as the “3 by 5” Initiative 
[3] and “Universal ART access by 2010” [2] were not 
achieved. In the current state of aﬀ airs, the likelihood of 
achieving, by 2015, the United Nations Millennium 
Development Goal (MDG) [4] targets and the “Getting to 
Zero” target [5] (the three zeros: zero new HIV infections, 
zero discrimination and zero AIDS-related deaths) of the 
Joint United Nations Programme on HIV/AIDS (UNAIDS) 
seem highly unlikely.
What is needed is to look forward, think of appropriate 
strategies and follow these with bold action. Such action 
needs to be guided by embedding operational research 
into programmes. From a programme perspective, 
operational research has been deﬁ ned as the search for 
knowledge on strategies, interventions or tools that can 
enhance the performance of health programmes in which 
the research is being conducted [6]. Th e authors of this 
paper have been involved with HIV/AIDS and related 
operational research at the programme level in sub-
Saharan Africa for many years.
From a programme perspective, we: a) highlight what 
needs to fundamentally change in our thinking and over-
all approach to the epidemic; and b) outline a number of 
key task areas for implementation and related operational 
research.
What needs to fundamentally change in our 
approach and thinking?
First, we need to imagine what the epidemic will look like 
in ﬁ ve to 10 years from now, as well as and the related 
programmatic challenges [7]. In this light, UNAIDS’s new 
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innovative Treatment 2.0 [8] is one example of the kind 
of approach that is needed. Th is approach describes how 
ART and HIV/AIDS care delivery systems should evolve 
to become simpler and more accessible on a wider level 
so as to have a signiﬁ cant impact in closing the current 
treatment gap, as well as in preventing HIV infection. 
Th is approach could save up to 10 million lives and 
prevent millions of new infections [8].
Second, in light of the massive current gaps in both 
treatment and prevention, we must look beyond main-
tain ing the status quo, which is not making an adequate 
“dent” in the epidemic.
Th ird, we need to overcome the current gaps of the 
traditional approach in documenting eﬃ  cacy of new tools 
and strategies, such as randomized controlled trials, and 
the science of how to translate these into large-scale ﬁ eld 
implementation. Social science, in particular, is critical 
here and assists in contextual understanding of various 
issues. For example, randomized controlled trials have 
shown that circumcised adult men may have some protec-
tion against HIV infection [9,10], and it is now recom-
mended that this surgical intervention be scaled up [11].
What is missing is a careful assessment of the potential 
consequences of large-scale, male circumcision initiatives 
that are currently taking place in six African countries 
[12]. It is quite possible that there are group or societal 
eﬀ ects, including behavioural changes that may reduce, 
or enhance, the eﬀ ect of male circumcision as a preven-
tive strategy. Th e randomized controlled trial design 
avoids such contextual considerations, but in real life, 
these trials play an important role, especially when 
considering implementation on a large scale [13,14]. In 
particular, social science research on context-speciﬁ c and 
gendered understanding and community messaging is 
likely to be vital in large-scale roll out.
Another example is the history of prevention of mother 
to child transmission of HIV (PMTCT), for which 
evidence and international recommendations exist [15]. 
However, contextual and feasibility challenges in sub-
Saharan Africa have greatly aﬀ ected uptake, with only 
about half of all HIV-infected pregnant mothers receiving 
antiretroviral drugs for PMTCT [1,12]. It is clear that 
gendered power relations within and beyond the house-
hold are likely to have a key role in whether or not mothers 
decide to engage with PMTCT programmes [16].
Finally, there is a need for new tools and new innovative 
strategies – even daring and bold action, things that most 
people might simply dismiss as being unfeasible – in 
diﬀ erent contexts.
Thinking ahead on task areas for implementation 
and related operational research
Although not exhaustive, Table 1 highlights a number of 
key task areas for implementation. Th e content of this 
panel was developed through a two-day workshop 
conducted by Médecins sans Frontières (MSF), which 
included a wide group of stakeholders from sub-Saharan 
Africa, all of whom had been directly involved with 
implementation and scale up of HIV/AIDS programmes 
in the region for many years: programme managers 
working in ministries of health; district level imple men-
ters; academics; patient activist groups; international 
HIV/AIDS experts; and researchers. Th e identiﬁ ed task 
areas needing attention in the next ﬁ ve to 10 years 
included: sustaining long-term HIV/AIDS funding; oﬀ er-
ing care to the ever-growing cohorts needing ART; 
getting those still waiting for ART on treatment; 
monitor ing patients in care; providing HIV care that is 
associated with a minimal risk of contracting tuberculosis 
(TB); investing in HIV prevention as a key to breaking 
the current epidemic and; building capacity for opera-
tional research. Th ese and related operational research 
areas are discussed in the following pages.
Sustaining long-term HIV/AIDS funding
Over recent years, there has been growing evidence of 
donor fatigue and what seems like a retreat from HIV/
AIDS funding by major donors. In 2010, the Global Fund 
to Fight AIDS, Tuberculosis and Malaria received 
US$11.7 billion in pledges compared with the $20 billion 
it had said it needed to meet the target of Universal 
Access. Th e United States-funded US President’s Emer-
gency Plan for AIDS Relief programme, which supports 
at least half of all people on HIV/AIDS treatment in 
developing countries, has ﬂ at-lined funding for the third 
year in a row [17].
Th ese are worrying signs, and economic recession is 
not the only culprit. Although not formally stated, issues 
of concern to donors include the fact that HIV/AIDS 
interventions have predominantly been vertical, with 
limited evidence of wider beneﬁ ts to health systems 
[18,19]. Th ere is some evidence demonstrating positive 
beneﬁ ts of HIV/AIDS interventions [20]. A few speciﬁ c 
examples include: the impact of ART in keeping health 
workers alive, particularly in sub-Saharan Africa [21]; the 
positive population impact of HIV/AIDS interventions in 
reducing crude mortality [22]; and community-wide 
beneﬁ ts in reducing the incidence of such diseases as TB 
[23-25] and malaria [26-27]. More examples of this type 
of operational research are needed to provide evidence of 
a broader impact both within and outside of the health 
sector, and this should help convince donors to invest in 
HIV/AIDS as a integral and worthwhile strategy towards 
achieving the health-related MDG targets [4]. In parti cu-
lar, operational research demonstrating a positive impact 
on maternal and child health services would be of great 
value [28].
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Table 1. Specifi c task areas related to the HIV/AIDS epidemic and related operational research issues
Task 1: Sustain long-term HIV/AIDS fi nancing
 Demonstrate how HIV/AIDS interventions contribute positively to improving healthcare services (directly or indirectly).
 Move from vertical to more integrated primary care delivery models.
 Show the positive impact of HIV/AIDS interventions at population level and clearly articulate how these link up with the achievement of the 2015 
Millennium Development Goals and beyond.
 Perform economic analysis to show the economic gains of HIV/AIDS interventions on health services and beyond (HIV/AIDS interventions are cost 
eff ective?). 
Task 2: Think of how to off er care to the ever growing cohort on ART ahead of time 
 Enhance simplicity, effi  ciency and cost eff ectiveness of the delivery mechanism and adapt these to diff erent contexts, for example: 
 Design simpler and cheaper ART protocols that are less toxic (safer) and easier for patients and health services (for both fi rst-line and second-line 
treatment).
 Pilot innovative models of delivery outside the health facilities (task shifting) and evaluate their eff ectiveness. 
 Community-based models
 Expert patient-based models
 Workplace models.
 Find tangible solutions to the human resources shortage for health in Africa.
 Think of sustainable drug supply and commodity management chains that do not end up with drug stock outs 
 Conduct social science research to better understand contextual issues infl uencing uptake of specifi c interventions.
Task 3: Think of those still waiting to get onto ART
 Off er ART earlier in line with revised WHO recommendations (41).
 Radically simplify ART eligibility assessment for patients in WHO stage 1 and 2 with point-of-care CD4 testing.
 Reduce high pre-ART attrition and test how to deliver specifi c packages of care (Cotrimoxazole preventive prophylaxis, , Isoniazid preventive therapy , 
Impregnated mosquito nets, nutritional support) that will support patients in pre-ART care and possibly keep them well and not yet needing ART.
Task 4: Monitor cohorts of people with HIV in care 
 Develop and assess how to set up simple and robust monitoring and reporting systems to follow retention and attrition (pre-ART and on ART) of 
thousands and eventually millions of patients.
 Work out how to set quality indicators and acceptable quality thresholds for mass scale up.
 Use point-of-care viral load tests for monitoring adherence, as well as deciding the optimal time to switch to second-line therapy.
 Use available and new technology to boost adherence, e.g., telephones and online tools.
Task 5: Provision of HIV care that is associated with a minimal risk of tuberculosis 
 Determine how best to implement TB case fi nding, infection control (air ventilation and patient fl ow organization) and isoniazid preventive therapy.
 Determine how to monitor these interventions.
Task 6: Invest in HIV prevention as this is a key to breaking the current epidemic
 Find innovative ways of improving HIV testing and knowledge of HIV status. 
 Assess feasibility of male circumcision on a large scale: 
 Through simpler and safer techniques 
 Integrating circumcision into preventive services (e.g., WHO’s Expanded Programme on Immunization)
 Enhancing community and civil society acceptance through partnerships.
 Pilot the feasibility and eff ectiveness of ART for prevention in the general population and high-risk groups.
 Radically simplify the PMTCT approach and protocol for health service providers and the mother (e.g., a one-pill-a-day standardized approach). 
 Assess feasibility of pre-exposure prophylaxis in high-risk groups and discordant couples.
 Understand the societal factors infl uencing uptake through social science research in relevant areas.
Task 7: Build capacity for conducting operational research: testing out new models of training
 Try out and assess diff erent types of training models and curricula that are performance and/or output based.
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How to off er care to the ever-growing cohort on ART?
More than ﬁ ve million people are on ART in low- and 
middle-income countries, and this case load is expected 
to double or triple in the next ﬁ ve to 10 years. Th e 
daunting challenges include: retaining and managing 
such patients [29]; providing an uninterrupted supply of 
drugs; ensuring adherence to medication; monitoring 
drug-related side eﬀ ects; and detecting and managing 
drug resistance. Th e underlying problem is that the 
increase in case loads and the consequent challenges 
occur in situations where there are serious shortages of 
health workers and weak health infrastructure. Sub-
Saharan Africa, for example, has a shortfall of almost ﬁ ve 
million health workers, more than double the numbers 
working today [30-31].
An additional problem is that most delivery models of 
care are labour intensive, with doctors and nurses playing 
a central role in service delivery and healthcare manage-
ment [32-33]. In addition, most ART and support 
services are run from hospitals, but most of these hos-
pitals are located in urban centres that patients from 
distant rural and semi-urban settings cannot access 
because of high transport and opportunity costs [34].
Encouraging evidence from decentralized, home-based 
models involving empowerment of non-clinical workers 
is emerging [35-37]. Importantly, a cluster randomized 
trial in Uganda demonstrated the cost eﬀ ectiveness of 
home-based HIV care using non-clinical workers [36]. 
Similarly, recent encouraging evidence from rural 
Mozam bique showed that self-forming groups of patients 
successfully conducted four vital activities: they facili-
tated monthly ART distributions to their group members 
in the community; they provided adherence and social 
support; they monitored outcomes; and they ensured 
that each group member underwent a clinical consul-
tation at least once every six months [37]
Several point-of-care CD4 and viral load tests are either 
on the market or in development, and oﬀ er an oppor-
tunity to decentralize monitoring to the patient level [38]. 
For example, people with diabetes can check their blood 
glucose levels almost anywhere in the world with point-
of-care tools. If a mother is worried that her child has a 
fever, she can use a thermometer to check if this is the 
case. Similarly, we need a simple test for monitoring viral 
load and CD4 counts that can be used at home, some-
thing akin to a “dipstick” that can be easily read and 
interpreted by lay people.
We already do have a single-tablet ﬁ xed-dose combi-
nation for ﬁ rst-line ART (Atripla), and this can help 
radically simplify the treatment protocol. If this can 
evolve further into a pill that has no side eﬀ ects and that 
has a high barrier to the development of resistance, it 
would be ideal. Further simpliﬁ cation could also be 
achieved if new regimens could be developed that allow 
greater spacing, for example, once-a-week treatment. 
Th is could ease stock and supply management as well as 
may be more cost advantageous. A decreased frequency 
of interaction with healthcare providers will free up HIV/
AIDS-dedicated human resources, lower out-of-pocket 
costs, such as transport fees for the care seeker [8], and 
would bring obvious advantages to the task of simplifying 
drug and commodity management.
In terms of operational research, what is needed is to 
implement and assess the feasibility and eﬀ ectiveness of 
delivery models for scale up of ART that move away from 
hospitals to communities and from clinical to non-
clinical staﬀ  [32,39,40]. Th ere is also a need to decen-
tralize point-of-care tools, such as CD4 and viral load 
tests, to the patient level and assess if self-testing can be 
used responsibly. Finally, there is a need to ﬁ nd ways of 
radically simplifying treatment protocols and assessing 
the impact that this has on patient and programme 
outcomes.
Getting those still waiting for ART onto treatment
At present, about six out of every 10 persons who need 
ART fail to access treatment [12]. When patients even-
tually get to the ART clinic, they are often weak, with 
advanced immune suppression, and despite treatment for 
opportunistic infections, a high proportion die early [8]. 
Reducing the waiting list for ART will need fast tracking 
of patients with simpler and less labour-intensive models 
and starting patients on ART earlier (with CD4 counts 
equal to or less than 350 cells/mm3 or less), as has been 
recommended by the World Health Organization 
(WHO) [41].
For example, a randomized controlled trial in Haiti 
showed convincingly that early initiation of ART was 
associated with a lower risk of death and incident risk of 
TB [42]. Operational evidence from Lesotho adds to this 
knowledge, showing that providing ART earlier leads to a 
68% reduction in deaths, a 27% reduction in new 
opportunistic diseases, a 63% reduction in hospitaliza-
tion, and a 39% reduction in people defaulting from care 
[43].
Th e use of WHO staging, as now recommended by 
WHO, avoids the need for CD4 tests to determine ART 
eligibility in those with advanced clinical disease (WHO 
stages 3 and 4) and thus shortens the road to ART. Th e 
challenge remains for patients in earlier clinical stages 
(WHO stages 1 and 2) who still need CD4 counts to 
assess their ART eligibility [41]. Finally, early infant 
diagnosis remains problematic, and in 54 reporting coun-
tries, only 15% of children born to HIV-infected mothers 
were tested for HIV in the ﬁ rst two months of life [12].
In terms of operational research, interesting challenges 
would include assessing the feasibility and eﬀ ectiveness 
of a point-of-care CD4 test at community or patient 
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levels as a gateway to facilitate access to ART for patients 
in WHO stages 1 and 2 [38]. Finding ways of delivering 
speciﬁ c packages of care (e.g., cotrimoxazole prophylaxis, 
isoniazid preventive therapy, nutritional support) to 
support patients in pre-ART care and to prevent pre-
ART attrition is required [44]. Finally, there is a need to 
develop and assess the feasibility of simple-to-use and 
accurate HIV diagnostic tools for infants with the aim of 
improving early HIV diagnosis in this highly vulnerable 
group.
Monitoring cohorts in care
Current monitoring systems are geared towards following 
patients for retention and adherence over time. Th e 
sources of information for such monitoring are patient 
cards and registers. Th e work involves manual, labour-
intensive reviews, which are unsustainable in the medium 
to longer term as reporting cohort outcomes involves 
hours of manual work, sifting through individual patient 
cards and registers of hundreds if not thousands of 
patients. Radical simpliﬁ cation is needed [45,46].
Encouraging ways forward include, for example, the 
use of robust electronic touch screen systems with auto-
mated cohort reporting [47,48]. Th e use of existing 
common technology, such as mobile phone messaging in 
Kenya to enhance adherence, reduced the need for 
patients to physically return to health facilities and 
proved eﬀ ective in enhancing ART adherence and viral 
load suppression [49]. In terms of operational research, 
there is a need to explore and further ﬁ eld test the 
potential of mobile phone technologies, including smart 
phones, and other innovative approaches linking the ever-
expanding technology with healthcare interventions. 
Piloting new and eﬀ ective ways of moving from district-
level reporting to facility-based monitoring and report-
ing, so that individual health facilities are able to manage 
and use their data in an eﬀ ective manner, is also much 
desired.
Provision of HIV care that is associated with a minimal risk 
of tuberculosis
WHO recommends the implementation of a package of 
the Th ree “I”s (isoniazid preventive therapy, intensiﬁ ed 
case ﬁ nding and infection control) as being essential to 
eﬀ ective HIV and TB care that is safe from nosocomial 
TB transmission [50,51]. Despite good evidence of the 
beneﬁ ts of this package, we have been far too slow in the 
application of knowledge into practice. Th e implemen-
tation gaps remain wide, with only 2.5% of 1.9 million 
eligible individuals screened for TB and only 8.7% of 16 
million people placed on isoniazid preventive therapy. 
Th ere are no global data on infection control [52]. Ways 
forward to enhance feasibility and uptake of each of these 
components are urgently needed [52,53].
Investing in HIV prevention strategies as a key to breaking 
the current epidemic
Prevention is key to breaking the current epidemic as this 
will close the pipeline of new cases that adds to existing 
case loads and mortality. Simulations have consistently 
shown that in the longer term, the most important driver 
of HIV prevalence and HIV case load is present-day HIV 
incidence. Halving of HIV incidence leads, with a eight- 
to 10-year lag, to halving the number of people needing 
to start ART, and considerably lower overall HIV 
prevalence [54] Th e ﬁ rst challenge is that only about 40% 
of people living with HIV currently know their HIV 
status. Second, there is a need to ﬁ nd feasible and 
acceptable ways of rolling out biomedical interventions, 
such as male circumcision at the community level 
[11,13,14]
Th ird, there is the dramatic impact of ART on 
prevention through viral suppression [8, 55] A recent 
study showed that ART used in discordant couples 
reduces HIV transmission (between couples) by 92% 
[56]. Mathematical modelling has also suggested the 
potential impact of oﬀ ering annual universal voluntary 
HIV testing and counselling, followed by immediate ART, 
irrespective of clinical stage or CD4 counts. Such a 
strategy would reduce the transmission rate (Ro) to <1 
(Ro being deﬁ ned as the number of secondary infections 
resulting from one primary infection in an otherwise 
susceptible population). As a consequence, the incidence 
of HIV would be reduced to less than one case per 
thousand persons per year within 10 years of full imple-
mentation of the strategy and the prevalence of HIV to 
less than 1% within 50 years [57-59].
Fourth, PMTCT remains a major challenge and ﬁ nding 
ways forward in increasing access and uptake is urgently 
needed. Even the current WHO protocol [15] is 
complicated; what is needed is a radical simpliﬁ cation of 
the PMTCT approach and protocol for both the provider 
and the mother. Finally, a randomized, double-blind 
multi-country trial among HIV-negative men and trans-
gender women who have sex with men showed that pre-
exposure prophylaxis with two oral ART drugs ( tenofovir 
and emtrictabine) was associated with a 44% reduction in 
HIV incidence compared with placebo, the prophylactic 
eﬀ ect being strongly correlated with detectable blood 
levels of the two drugs [60,61]. Th e CAPRISA 004 trail 
also demonstrated the eﬀ ectiveness and safety of a 1% 
vaginal gel formulation of tenofovir for the prevention of 
HIV acquisition in women [62].
In terms of operational research, there is an urgent 
need to ﬁ nd ways of increasing knowledge of HIV status 
by increasing the uptake of HIV testing and linkages to 
care [8] Th e feasibility and acceptability of integration of 
circumcision into routine preventive activities, such as 
WHO’s Expanded Programme on Immunization, or as 
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stand-alone services needs to be explored. In terms of 
ART for prevention at the community level, there is an 
urgent need to think around the challenges of 
acceptability and feasibility of this approach in the 
general population and among high-risk groups [57-59]. 
For PMTCT, a one-pill-a-day ART, a standardized 
approach that covers both prevention of transmission 
and early treatment of the infected mother, should be 
tried. Finally, feasibility of implementing pre-exposure 
prophylaxis should be explored under operational condi-
tions, and to save on costs, the eﬃ  cacy of pre-exposure 
prophylaxis only at the time of sexual exposure should be 
examined. Combining implementation and social science 
research in all these areas is vital.
Building capacity for conducting operational research: 
testing out new models of training
Programmes in low-income countries and, particularly in 
sub-Saharan Africa, need to develop the capacity to 
conduct operational research [6,30,63]. Some of the 
programmatic challenges include inadequate or irrele-
vant research questions, lack of time and opportunity, 
lack of research infrastructure, and lack of knowledge 
about how to translate research ﬁ ndings into policy and 
practice [6]. In particular, capacity to conduct and 
publish research is seriously lacking [64]. Programme-
embedded models with strong on-the-job mentorship are 
urgently needed. Training models will need to take 
programmatic hurdles into consideration, to be perfor-
mance and output linked, and able to deliver in a 
relatively short time. Two examples of such approaches 
include the International Union Against Tuberculosis 
and Lung Disease-MSF approach to sustainable opera-
tional research and that oﬀ ered by the US Centers for 
Disease Control and Prevention [65,66,67]. Operational 
research is also needed to evaluate the existing models 
and tailor them to ensure outputs.
Summary
Turning the tide of the devastating HIV/AIDS epidemic 
will require us to think ahead about the challenges with 
regards to policy, care and prevention that we will be 
facing in the years to come. It is beholden upon us both 
as implementers and researchers to act now through bold 
action and operational research so that will be able to 
face up to current and impending tasks related to the 
epidemic.
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